Introduction {#s1}
============

Scoring systems based on classic risk factors, including sex, age, hypertension, dyslipidemia, and smoking, predict the future risk of cardiovascular events or death [@pone.0033084-Anderson1]--[@pone.0033084-Wilson1]; however, these risk factors explain only part of cardiovascular risk.

Thus, attempts have been made to improve the prediction of cardiovascular risk by adding multiple novel biomarkers to the classic risk factors. These biomarkers have included markers of inflammation, kidney function, cardiac damage, endothelial function, metabolism, and oxidative stress, among others [@pone.0033084-Blankenberg1]--[@pone.0033084-Zethelius1].

However, these novel markers\' abilities to improve prediction were mostly disappointing. Many studies failed to detect a clinically relevant improvement in risk prediction [@pone.0033084-Blankenberg2], [@pone.0033084-Melander1], [@pone.0033084-Wang1]. Biomarkers that appeared to improve prediction in some studies [@pone.0033084-Blankenberg1], [@pone.0033084-Zethelius1] did not perform well in other cohorts [@pone.0033084-Blankenberg2].

Differences in hormone levels are associated with cardiovascular risk. Both elevated and suppressed thyrotropin concentrations have been associated with increased cardiovascular mortality, though not consistently [@pone.0033084-Ochs1]. Low levels of insulin-like growth factor-1 (IGF-1), a metabolic and anabolic hormone as well as a mediator of growth hormone action, have been associated with increased cardiovascular mortality in some studies [@pone.0033084-Laughlin1], [@pone.0033084-Friedrich1], but not in all [@pone.0033084-Saydah1]. In men, low testosterone levels predict cardiovascular and all-cause mortality [@pone.0033084-Haring1]--[@pone.0033084-Laughlin2]. Hemoglobin A1c (HbA1c) predicted cardiovascular events in several studies, independently of diabetes [@pone.0033084-Adams1]--[@pone.0033084-Khaw1], although these results were not confirmed by another study [@pone.0033084-Chonchol1].

In addition, recent studies suggest that measures of abdominal obesity, such as the waist-to-height ratio (WHtR), are associated with cardiovascular risk, independent of classic cardiovascular risk factors [@pone.0033084-Gelber1], [@pone.0033084-Schneider1]. To our knowledge, no one has studied whether a multimarker approach that includes endocrine and metabolic parameters along with abdominal obesity will improve the predictive value of classic cardiovascular risk factors.

We hypothesized that a comprehensive set of easily assessed biomarkers that reflect different potential pathways of cardiovascular risk, including hormonal imbalance, glucose metabolism, abdominal obesity, inflammation, and kidney damage, adds incrementally to the use of conventional risk factors to predict cardiovascular and all-cause death.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

The Study of Health in Pomerania (SHIP) is a longitudinal, representative, population-based cohort study in West Pomerania, a region in northeast Germany. Baseline data was collected from 1997 through 2001. A total of 4,308 subjects (response proportion: 69%) participated [@pone.0033084-John1], [@pone.0033084-Vlzke1]. All participants gave written informed consent. The study conformed to the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of the University of Greifswald.

Of the 4,308 participants, 18 pregnant women, 63 with incomplete conventional cardiovascular risk factor information and 260 with history of major cardiovascular events (stroke, myocardial infarction or heart surgery) at baseline were excluded, resulting in a study population of 3,967 subjects. Vital status information was acquired at annual intervals from the time of enrollment through December 2009. Subjects were censored at either death or failure to follow-up. The median duration of follow-up was 10.0 years (25^th^ percentile 9.3; 75^th^ percentile 10.0). Death certificates were coded by a certified nosologist according to the International Classification of Diseases, 10th revision (ICD10). Additionally, two internists (H.W. and M.D.) independently validated the underlying causes of death and performed a joint reading together with a third internist (H.V.) in cases of disagreement. Cardiovascular death included Codes I10 to I79.

Clinical assessments {#s2b}
--------------------

Information on age, sex, and medical history was collected with computer-aided personal interviews. Smoking status was assessed by self-report, and subjects were categorized as either current smokers (at least one cigarette per day within the past year) or non-smokers. Anthropometric characteristics were measured according to written, standardized instructions in accordance with World Health Organization standards (WHO 1987). Waist circumference was measured to the nearest 0.1 cm midway between the lower rib margin and the iliac crest in the horizontal plane, using an inelastic tape measure. Blood pressure was measured three times with an appropriate-sized cuff after five minutes of rest in a sitting position, and the mean of the second and third measurement was recorded. The definition of diabetes mellitus was based on self-reported physician\'s diagnosis or self-reported use of antidiabetic medication in the last seven days. The history of cardiovascular disease (CVD) was based on a self-reported history of myocardial infarction, stroke or cardiac surgery.

Laboratory measurements {#s2c}
-----------------------

Non-fasting blood samples were drawn from the cubital vein, with the patient in the supine position. A urine sample was collected. The samples were taken between 07:00 a.m. and 04:00 p.m. and analyzed immediately or stored at −80°C until biomarkers could be measured. In addition, internal quality controls were performed at least daily.

Urine samples were stored for a maximum of 2 days until measurement. Serum creatinine levels were determined with the Jaffé method (Hitachi 717; Roche Diagnostics, Germany). The urinary albumin concentration was determined with a Behring Nephelometer (Siemens BN albumin; Siemens Healthcare, Marburg, Germany). Total and high-density lipoprotein (HDL) cholesterol were measured photometrically (Hitachi 704; Roche, Mannheim, Germany).

Serum IGF-1 was determined with automated two-site chemiluminescence immunoassays (Nichols Advantage; Nichols Institute Diagnostica GmbH, Bad Vilbel, Germany). Total testosterone levels were measured with competitive chemiluminescent enzyme immunoassays on an Immulite 2500 analyzer (Siemens Immulite 2500 Total Testosterone, ref. L5KTW, Lot 110; Siemens Healthcare Medical Diagnostics, Bad Nauheim, Germany). Serum thyrotropin levels were measured with immunochemiluminescence (Byk Sangtec Diagnostica GmbH, Frankfurt, Germany). HbA1c levels were determined with high-performance liquid chromatography (Bio-Rad Diamat, Munich, Germany). Plasma fibrinogen concentrations were assayed as described by Clauss (19), using an Electra 1600 analyzer (Instrumentation Laboratory, Barcelona, Spain). HsCRP was determined immunologically on a Behring Nephelometer II with commercially available reagents from Dade Behring (Dade Behring, Eschborn, Germany).

Statistical analyses {#s2d}
--------------------

Categorical data were expressed as percentages; continuous data were expressed as medians (25^th^ percentile; 75^th^ percentile). Continuous variables were truncated at the 1^st^ and 99^th^ percentile. Univariate analysis was performed, with χ^2^ testing for categorical variables and Mann--Whitney U-tests for continuous distributions. For regression analyses, skewed variables were log-transformed.

We included the following parameters as conventional risk factors: age (continuous); sex (binary); systolic blood pressure (continuous); antihypertensive medication (binary); HDL cholesterol (continuous); total cholesterol (continuous); diabetes (binary); and current smoking (binary). We assessed the following biomarkers as continuous variables, analyzing the effects of an increase of one standard deviation (SD) from the mean: thyrotropin, IGF-1, testosterone, hsCRP, fibrinogen, HbA1c, creatinine, urinary albumine-to-creatinine ratio (UACR), and WHtR. Additionally, we analyzed cutoffs that were considered clinically useful and were derived from the literature for the following variables: thyrotropin below and above the reference range versus the reference range (0.25--2.12 mIU/l) [@pone.0033084-Vlzke2]; IGF-1 below the 10^th^ sex- and age-specific percentile [@pone.0033084-Friedrich1]; and testosterone below 10.4 nmol/l [@pone.0033084-Haring1]. Testosterone was measured in men only, and all analyses that included testosterone were performed in men only.

We proceeded in four steps to assess the prediction of cardiovascular death. First, we performed Cox proportional hazards regression analyses for single biomarkers, unadjusted and adjusted for conventional risk factors, to predict cardiovascular death. Second, we included all biomarkers that were significant after adjustment into a prediction model, using backward elimination with conventional risk factors forced into the model. Third, we used the C-statistic, as described by Pencina et al. [@pone.0033084-Pencina1], to compare the predictive values of conventional risk factors with single, novel risk factors and the models built in the second step [@pone.0033084-Newson1]. Finally, we classified subjects into groups with low (\<2%), moderate (2% to 9%) and high (\>9%) risk, based on the recommendations of the European Society of Cardiology [@pone.0033084-Conroy1], and calculated the net reclassification improvement (NRI) for cardiovascular death. The bias-corrected accelerated bootstrap resampling procedure of Efron and Tibshirani was used to obtain 95% confidence intervals for NRIs. Observed risk at 10-years estimated from Kaplan-Meier curve were used to estimate the expected number of subjects who died and who did not die at 10-year follow-up.

In secondary analyses, we repeated the first three steps with all-cause death as outcome. A two-sided p-value of \<0.05 was considered statistically significant. Statistical analyses were performed with SAS 9.1 (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Study sample {#s3a}
------------

Baseline characteristics are shown in [table 1](#pone-0033084-t001){ref-type="table"}. During the 38,638 person-years of follow-up, we observed 339 (8.6%) all-cause deaths (rate per 1,000 person years: 8.8), including 103 (2.6%) deaths due to cardiovascular disease (rate per 1,000 person years: 2.7).

10.1371/journal.pone.0033084.t001

###### Baseline characteristics.

![](pone.0033084.t001){#pone-0033084-t001-1}

  Characteristics                               N (m/w)           Men                Women
  ------------------------------------------- ----------- ------------------- -------------------
  Age, years                                   1892/2075      50 (36; 63)         48 (35; 61)
  Current Smokers, %                           1892/2075         38.2                28.6
  Diabetes, %                                  1892/2075          7.7                 6.7
  Antihypertensive medication, %               1892/2075         26.3                26.7
  Systolic blood pressure, mm Hg               1892/2075    141 (129; 153)      126 (114; 142)
  Total cholesterol, mg/dl                     1892/2075    222 (193; 251)      218 (189; 251)
  HDL cholesterol, md/dl                       1892/2075      48 (41; 58)         60 (50; 71)
  *Biomarkers*                                                                
  Waist-to-height ratio                        1892/2075   0.54 (0.50; 0.59)   0.50 (0.44; 0.57)
  HbA1c, %                                     1888/2066    5.4 (5.0; 5.8)      5.2 (4.8; 5.6)
  IGF-1, ng/ml                                 1784/1971    133 (104; 170)      135 (102; 174)
  Testosterone, nmol/l                          1812/0     16.0 (12.7; 20.3)          \-
  Thyrotropin, mU/l                            1872/2046   0.65 (0.43; 0.94)   0.68 (0.44; 1.02)
  High-sensitive CRP, mg/l                     1745/1917   1.25 (0.65; 2.82)   1.49 (0.68; 3.57)
  Fibrinogen, g/l                              1887/2067   2.80 (2.43; 3.30)   2.90 (2.54; 3.40)
  Serum creatinine, µmol/l                     1884/2073      90 (83; 98)         77 (71; 83)
  Urinary Albumin-to-Creatinine Ratio, mg/g    1735/1753    7.1 (4.3; 15.0)     9.3 (5.8; 17.3)

N(m/w)  =  number of men and women with data on the respective parameter; HDL  =  high-density lipoprotein; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; CRP  =  C-reactive protein. Continuous data are expressed as median (25th; 75th percentile); nominal data are given as percentages.

Prediction of events by single biomarkers {#s3b}
-----------------------------------------

The results of the Cox regression analyses for predicting cardiovascular death with single biomarkers are shown in [table 2](#pone-0033084-t002){ref-type="table"}. WHtR, HBA1c, testosterone below 10.4 nmol/l, hsCRP, and IGF-1 levels below the 10^th^ sex- and age-specific percentile remained significant predictors after adjustment for conventional risk factors.

10.1371/journal.pone.0033084.t002

###### Prediction of cardiovascular death by single biomarkers.

![](pone.0033084.t002){#pone-0033084-t002-2}

                                     Trans-formation       SD        Total   Events   Unadjusted HR (95%CI)     p      Adjusted HR (95%CI)[\*](#nt103){ref-type="table-fn"}     p
  --------------------------------- ----------------- ------------- ------- -------- ----------------------- -------- ------------------------------------------------------ --------
  WHtR, 1-SD increase                      \-             0.08       3967     103       2.31 (1.95; 2.75)     \<.001                    1.41 (1.13; 1.78)                     0.003
  HbA1c, 1-SD increase                     \-             0.90%      3954     102       1.64 (1.51; 1.78)     \<.001                    1.34 (1.13; 1.58)                     0.001
  IGF-1                                                57.6 ng/ml    3755      96                                                                                            
  \<10th percentile                        \-                                           2.32 (1.41; 3.84)     0.001                     2.43 (1.46; 4.05)                     0.001
  1-SD increase                            \-                                           0.37 (0.28; 0.50)     \<.001                    0.76 (0.56; 1.04)                      0.09
  Testosterone                                         6.01 nmol/l   1812      58                                                                                            
  \<10.4 nmol/l                            \-                                           3.47 (1.99; 6.06)     \<.001                    1.90 (1.05; 3.47)                      0.04
  1-SD increase                            \-                                           0.64 (0.48; 0.86)     0.003                     0.89 (0.68; 1.15)                      0.37
  Thyrotropin                                           0.77 mU/l    3918     101                                                                                            
  1-SD increase                            log                                         0.81 (0.68; 0.967)      0.02                     1.03 (0.86; 1.22)                      0.78
  \<0.25 mU/l (ref.: 0.25--2.12)           \-                                           1.92 (1.11; 3.32)      0.02                     1.00 (0.57; 1.75)                      1.00
  \>2.12 mU/l (ref.: 0.25--2.12)           \-                                               no events           \-                          no events                           \-
  hsCRP, 1-SD increase                     log          1.10 mg/l    3662      91       2.07 (1.71; 2.51)     \<.001                    1.60 (1.29; 1.98)                     \<.001
  Fibrinogen, 1-SD increase                log          0.22 g/l     3954     102       1.82 (1.52; 2.19)     \<.001                    1.21 (0.98; 1.48)                      0.07
  Serum creatinine, 1-SD increase          log         0.17 µmol/l   3957     102       1.49 (1.34; 1.66)     \<.001                    1.11 (0.93; 1.33)                      0.27
  UACR, 1-SD increase                      log          1.06 mg/g    3488      96       1.72 (1.48; 1.99)     \<.001                    1.09 (0.91; 1.30)                      0.36

SD  =  standard deviation; HR  =  hazard ratio; CI  =  confidence interval; WHtR  =  waist-to-height-ratio; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; hsCRP  =  high-sensitive C-reactive protein; UACR  =  urinary albumin-to-creatinine ratio.

Models were adjusted for age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, antihypertensive medication, diabetes, and current smoking.

For all-cause death, WHtR, hsCRP, fibrinogen, IGF-1 levels below the 10^th^ percentile, and testosterone below 10.4 nmol/l remained significant predictors after adjustment for conventional risk factors ([table 3](#pone-0033084-t003){ref-type="table"}).

10.1371/journal.pone.0033084.t003

###### Prediction of all-cause death by single biomarkers.

![](pone.0033084.t003){#pone-0033084-t003-3}

                                     Trans-formation       SD        Total   Events   Unadjusted HR (95%CI)     p      Adjusted HR (95%CI)[\*](#nt105){ref-type="table-fn"}     p
  --------------------------------- ----------------- ------------- ------- -------- ----------------------- -------- ------------------------------------------------------ --------
  WHtR, 1-SD increase                      \-             0.08       3967     339       1.92 (1.74; 2.12)     \<.001                    1.19 (1.05; 1.36)                     0.008
  HbA1c, 1-SD increase                     \-             0.90%      3954     338       1.44 (1.36; 1.53)     \<.001                    1.09 (0.98; 1.22)                      0.11
  IGF-1                                                57.6 ng/ml    3755     319                                                                                            
  \<10th percentile                        \-                                           1.47 (1.07; 2.02)      0.02                     1.60 (1.16; 2.20)                     0.004
  1-SD increase                            \-                                           0.47 (0.40; 0.55)     \<.001                    0.87 (0.75; 1.03)                      0.10
  Testosterone                                         6.01 nmol/l   1812     204                                                                                            
  \<10.4 nmol/l                            \-                                           2.24 (1.61; 3.11)     \<.001                    1.53 (1.08; 2.16)                      0.02
  1-SD increase                            \-                                           0.85 (0.73; 0.98)      0.03                     1.01 (0.88; 1.15)                      0.94
  Thyrotropin                                           0.77 mU/l    3918     331                                                                                            
  1-SD increase                            log                                          0.85 (0.77; 0.94)     0.002                     1.06 (0.96; 1.17)                      0.24
  \<0.25 mU/l (ref.: 0.25--2.12)           \-                                           1.65 (1.20; 2.29)     0.002                     0.94 (0.68; 1.31)                      0.71
  \>2.12 mU/l (ref.: 0.25--2.12)           \-                                           1.01 (0.54; 1.90)      0.98                     1.06 (0.56; 2.02)                      0.85
  hsCRP, 1-SD increase                     log          1.10 mg/l    3662     315       1.65 (1.49; 1.83)     \<.001                    1.30 (1.16; 1.46)                     \<.001
  Fibrinogen, 1-SD increase                log          0.22 g/l     3954     337       1.65 (1.49; 1.82)     \<.001                    1.16 (1.04; 1.30)                     0.008
  Serum creatinine, 1-SD increase          log         0.17 µmol/l   3957     337       1.41 (1.32; 1.51)     \<.001                    1.08 (0.97; 1.20)                      0.14
  UACR, 1-SD increase                      log          1.06 mg/g    3488     318       1.51 (1.39; 1.65)     \<.001                    1.07 (0.97; 1.19)                      0.18

SD  =  standard deviation; HR  =  hazard ratio; CI  =  confidence interval; WHtR  =  waist-to-height-ratio; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; hsCRP  =  high-sensitive C-reactive protein; UACR  =  urinary albumin-to-creatinine ratio.

Models were adjusted for age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, antihypertensive medication, diabetes, and current smoking.

Risk prediction with combined biomarkers and risk factors {#s3c}
---------------------------------------------------------

[Table 4](#pone-0033084-t004){ref-type="table"} shows the results of backward elimination models that included all significant biomarkers from the previous step with conventional risk factors forced into the model for cardiovascular death. HsCRP, HbA1c, and low IGF-1 remained significant predictors after backward elimination. In men, low testosterone was not retained in the model after backward elimination. Therefore, we did not continue with separate analyses by sex. HsCRP and low IGF-1 remained significant predictors for all-cause death ([table 5](#pone-0033084-t005){ref-type="table"}).

10.1371/journal.pone.0033084.t004

###### Prediction of cardiovascular death by backward-elimination.

![](pone.0033084.t004){#pone-0033084-t004-4}

                                                HR (95%CI)[\*](#nt107){ref-type="table-fn"}     p
  -------------------------------------------- --------------------------------------------- --------
  *Conventional cardiovascular risk factors*                                                 
  age, per year                                              1.13 (1.10; 1.16)                \<.001
  Smoker                                                     1.92 (1.13; 3.28)                 0.02
  Antihypertensive medication                                1.15 (0.72; 1.83)                 0.56
  HDL cholesterol, 1-SD increase                             0.77 (0.58; 1.01)                 0.06
  Female                                                     0.67 (0.42; 1.07)                 0.10
  Diabetes                                                   1.50 (0.83; 2.71)                 0.18
  Systolic BP, 1-SD increase                                 1.18 (0.95; 1.47)                 0.13
  Total cholesterol, 1-SD increase                           0.95 (0.74; 1.20)                 0.66
  *Biomarkers*                                                                               
  HbA1c, 1-SD increase                                       1.28 (1.07; 1.51)                0.005
  hsCRP, 1-SD increase                                       1.50 (1.21; 1.87)                \<.001
  IGF-1 \<10th percentile                                    2.18 (1.30; 3.67)                0.003

BP  =  blood pressure; SD  =  standard deviation; HR  =  hazard ratio; CI  =  confidence interval; WHtR  =  waist-to-height-ratio; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; hsCRP  =  high-sensitive C-reactive protein; UACR  =  urinary albumin-to-creatinine ratio; Cox regression analysis with backward elimination with a p-value of 0.05.

Conventional cardiovascular risk factors were forced into the model.

10.1371/journal.pone.0033084.t005

###### Prediction of all-cause death by backward-elimination.

![](pone.0033084.t005){#pone-0033084-t005-5}

                                                HR (95%CI)[\*](#nt109){ref-type="table-fn"}     p
  -------------------------------------------- --------------------------------------------- --------
  *Conventional cardiovascular risk factors*                                                 
  age, per year                                              1.10 (1.09; 1.11)                \<.001
  Smoker                                                     2.17 (1.66; 2.84)                \<.001
  Antihypertensive medication                                1.20 (0.93; 1.54)                 0.16
  HDL cholesterol, 1-SD increase                             0.99 (0.87; 1.12)                 0.86
  Female                                                     0.51 (0.39; 0.65)                \<.001
  Diabetes                                                   1.79 (1.34; 2.38)                \<.001
  Systolic BP, 1-SD increase                                 1.03 (0.91; 1.16)                 0.66
  Total cholesterol, 1-SD increase                           1.11 (0.98; 1.25)                 0.09
  *Biomarkers*                                                                               
  hsCRP, 1-SD increase                                       1.29 (1.15; 1.45)                \<.001
  IGF-1 \<10th percentile                                    1.49 (1.08; 2.07)                 0.02

BP  =  blood pressure; SD  =  standard deviation; HR  =  hazard ratio; CI  =  confidence interval; WHtR  =  waist-to-height-ratio; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; hsCRP  =  high-sensitive C-reactive protein; UACR  =  urinary albumin-to-creatinine ratio; Cox regression analysis with backward elimination with a p-value of 0.05.

Conventional cardiovascular risk factors were forced into the model.

[Table 6](#pone-0033084-t006){ref-type="table"} shows the C-statistics for cardiovascular death. Adding biomarkers to all conventional risk factors lead to a significant (p  =  0.02) but slight change in the C-statistic for cardiovascular death from 0.898 (95%-CI 0.873--0.923) to 0.910 (95%-CI 0.886--0.934). For all-cause death, the C-statistic changed (p  =  0.09) from 0.849 (95%-CI 0.830--0.868) to 0.853 (95%-CI 0.833--0.872) after biomarkers were included ([table 7](#pone-0033084-t007){ref-type="table"}). The reclassification for cardiovascular death was 10.61% (95%-CI −0.28--24.86) as shown in [table 8](#pone-0033084-t008){ref-type="table"}.

10.1371/journal.pone.0033084.t006

###### Improvement of prediction of cardiovascular death by biomarkers.

![](pone.0033084.t006){#pone-0033084-t006-6}

                                                   C-statistic[\*](#nt111){ref-type="table-fn"}of cardiovascular deaths with 95% CI(3602 subjects, 91 events)   Net reclassification improvement with95% CI[†](#nt112){ref-type="table-fn"} (%)
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------
  Conventional cardiovascular risk factors only                                               0.898 (0.873; 0.923)                                             
  *Biomarkers*                                                                                                                                                 
  HbA1c, 1-SD increase                                                                        0.902 (0.877; 0.927                                                                             4.52 (−3.25; 17.39)
  hsCRP, 1-SD increase                                                                        0.906 (0.881; 0.930)                                                                            4.71 (−2.70; 15.92)
  IGF-1 \<10th percentile                                                                     0.902 (0.877; 0.927)                                                                            5.80 (−0.66; 21.81)
  All biomarkers                                                                              0.910 (0.886; 0.934)                                                                           10.61 (−0.28; 24.86)

CI  =  confidence interval; SD  =  standard deviation; WHtR  =  waist-to-height-ratio; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; hsCRP  =  high-sensitive C-reactive protein. Conventional cardiovascular risk factors include age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, antihypertensive medication, diabetes, and current smoking.

For conventional risk factors only or conventional risk factors + biomarkers.

The bias-corrected accelerated bootstrap resampling procedure was used to calculate 95% confidence intervals.

10.1371/journal.pone.0033084.t007

###### Improvement of prediction of all-cause death by biomarkers.

![](pone.0033084.t007){#pone-0033084-t007-7}

                                                   C-statistic[\*](#nt114){ref-type="table-fn"}of all-causedeath with 95% CI(3602 subjects, 311 events)
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------
  Conventional cardiovascular risk factors only                                            0.849 (0.830; 0.868)
  *Biomarkers*                                    
  hsCRP, 1-SD increase                                                                     0.852 (0.833; 0.871)
  IGF-1 \<10th percentile                                                                  0.850 (0.830; 0.869)
  All biomarkers                                                                           0.853 (0.833; 0.872)

CI  =  confidence interval; SD  =  standard deviation; WHtR  =  waist-to-height-ratio; HbA1c  =  hemoglobin A1c; IGF-1  =  Insulin-like growth factor 1; hsCRP  =  high-sensitive C-reactive protein. Conventional risk factors include age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, antihypertensive medication, diabetes, and current smoking.

For conventional cardiovascular risk factors only or conventional cardiovascular risk factors + biomarkers.

10.1371/journal.pone.0033084.t008

###### Reclassification of cardiovascular deaths using the model with both conventional cardiovascular risk factors and biomarkers retained after backward-elimination.

![](pone.0033084.t008){#pone-0033084-t008-8}

                                                               Model with conventional riskfactors + biomarkers   Reclassified intonew category, %                                      
  ----------------------------------------------------------- -------------------------------------------------- ---------------------------------- ------- ------ -------------------- ------
  **\<2%**                                                                                                                                                                              
  Subjects included                                                                  2631                                        58                    4     2693          0.0           2.2
  Subjects who died of CVD[\*](#nt116){ref-type="table-fn"}                           25                                         6                     0      31           0.0           19.4
  Subjects who did not die of CVD                                                    2606                                        52                    0     2658          0.0           2.0
  Observed risk, %[†](#nt117){ref-type="table-fn"}                                   0.93                                      10.73                   0                                
  **2%; 9%**                                                                                                                                                                            
  Subjects included                                                                  153                                        434                   58     645           23.7          9.0
  Subjects who died of CVD[\*](#nt116){ref-type="table-fn"}                           4                                          25                    9      38           10.5          23.7
  Subjects who did not die of CVD                                                    149                                        409                   49     607           24.5          8.1
  Observed risk, %[†](#nt117){ref-type="table-fn"}                                   2.56                                       5.80                 16.00                              
  **\>9%**                                                                                                                                                                              
  Subjects included                                                                   0                                          75                   189    264           28.4          0.0
  Subjects who died of CVD[\*](#nt116){ref-type="table-fn"}                           0                                          4                    25      29           13.8          0.0
  Subjects who did not die of CVD                                                     0                                          71                   164    235           30.2          0.0
  Observed risk, %[†](#nt117){ref-type="table-fn"}                                    0                                         5.79                 13.15                              
  **Total**                                                                                                                                                                             
  Subjects included                                                                  2784                                       567                   251    3602                       
  Subjects who died of CVD[\*](#nt116){ref-type="table-fn"}                           28                                         36                   35      99    **NRI  =  10.61%**  
  Subjects who did not die of CVD                                                    2756                                       531                   216    3503                       
  Observed risk, %[†](#nt117){ref-type="table-fn"}                                   1.02                                       6.34                 13.80                              

CVD  =  cardiovascular disease; NRI  =  net reclassification improvement. Conventional cardiovascular risk factors include age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, body-mass-index, antihypertensive medication, lipid-lowering medication, diabetes, and current smoking.

10-year Kaplan-Meier estimates were used to estimate the number of subjects who died and who did not die.

Observed risk at 10-years was estimated from the Kaplan-Meier curve.

Discussion {#s4}
==========

In this population-based cohort study, we analyzed whether combining endocrine and metabolic parameters with a marker of abdominal obesity improved the prediction of cardiovascular death with conventional risk factors. We identified a set of additional biomarkers, including low IGF-1, HbA1c, and hsCRP that caused a moderate but significant improvement in the prediction of cardiovascular deaths and correctly reclassified 11% of the population at risk. The predictive value was stronger for cardiovascular than for all-cause death. This result is not surprising because the risk factors selected were aimed at cardiovascular risk and not at other causes of death.

Our results confirm the findings of previous studies showing that hsCRP is a significant predictor of cardiovascular risk in a multimarker approach [@pone.0033084-Blankenberg2]--[@pone.0033084-Zethelius1]. Our results extend the findings of previous reports by assessing the associations of HbA1c, and low IGF-1 in this context.

HbA1c was included in one multimarker study, but only in subjects with diabetes [@pone.0033084-Ridker1]. Several studies focusing on HbA1c found a predictive role independent of diabetes \[19--219\]. We confirmed this role in combination with other biomarkers.

Testosterone in men and thyrotropin did not improve prediction. Although low levels of testosterone have been shown to predict mortality even after adjustment for cardiovascular risk factors [@pone.0033084-Laughlin2], the fact that the associations became weaker after adjustment in our study suggests that the effects of testosterone are mediated by cardiovascular risk factors. This result is consistent with previous studies showing that testosterone is associated with cardiovascular risk factors [@pone.0033084-Haring2], [@pone.0033084-Schneider2]. Similar associations may play a role in the results found for thyrotropin [@pone.0033084-Volzke1].

Low IGF-1 was a significant predictor. Experimental data show IGF-1\'s protective effects against systemic inflammation, insulin resistance, and free fatty acid production, all of which are consequences of obesity [@pone.0033084-Rajpathak1]. IGF-1 remained a significant predictor among parameters that reflect these different pathways. This finding suggests that additional parameters are involved in the association between IGF-1 and cardiovascular death. Possibly, the effects of IGF-1 on endothelial function and cardiac growth and function [@pone.0033084-Juul1], [@pone.0033084-Empen1] or other, unknown factors play a part.

Previous studies have shown that WHtR is a strong and linear predictor of cardiovascular risk, compared with other measures of abdominal and overall obesity [@pone.0033084-Gelber1], [@pone.0033084-Schneider1], [@pone.0033084-Schneider3] whereas BMI shows a U-shaped association with cardiovascular risk and mortality [@pone.0033084-Flegal1]--[@pone.0033084-Gruberg1]. WHtR was not significant in this multimarker approach. Most likely, this is due to the fact that abdominal obesity, as measured by the WHtR, increases risk by promoting conventional cardiovascular risk factors.

The identification of biomarkers to improve the ability to predict cardiovascular risk has been a focus of interest in recent years. Our results show a modest improvement in prediction compared with other studies [@pone.0033084-Blankenberg2]--[@pone.0033084-Wang1]. The inclusion of IGF-1 and HbA1c may have contributed to this effect. Other studies found higher incremental effects of biomarkers than our study [@pone.0033084-Blankenberg1], [@pone.0033084-Zethelius1]. Selection of high-risk patients or different outcomes might play a part in these findings.

It has been shown that biomarkers can result in relevant reclassification, even in the absence of significant increases in C-statistics [@pone.0033084-Ridker1]. In our study, 11% of subjects were correctly net reclassified by the new biomarkers. Generally, one can expect that the lower the costs for a biomarker are the greater is the willingness to accept small increments in discrimination.

We selected biomarkers that can be easily obtained in every-day clinical practice. Therefore, the increment in our study, though only moderate, might be relevant if validated, given the low cost and effort associated with biomarker assessment -- HbA1c is a routine laboratory parameter and hsCRP is increasingly used in risk assessment. IGF-1 is mainly used as marker of pathological changes in growth hormone secretion in an endocrine setting. All of the biomarkers we measured can be assessed clinically or in blood and do not require fasting.

Several limitations need to be addressed. First, because we aimed to explore new biomarkers, our findings need validation in additional cohorts. We did not test other potentially relevant markers, such as troponin or B-type natriuretic peptide. We expect that these factors are more relevant in populations with higher baseline risks of cardiac damage than our sample had. As in any study of risk prediction, multiple testing is an issue, although we tried to minimize the number of tests we administered. In addition, we only assessed cardiovascular and all-cause mortality. We do not know if our findings are generalizable to other cardiovascular events.

In summary, we found a set of biomarkers that improve the prediction of cardiovascular death. The effort required to assess these parameters is low. Thus, the increase in the C-statistic, though only moderate, and the net reclassification of 11% could have a clinical benefit, once validated.
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